Cathy McMorris Rodgers

FILE - This Aug. 2, 2018 file photo shows the U.S. Food and Drug Administration building behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md. The Food and Drug Administration has issued a negative review of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease. The review comes ahead of a meeting this week for outside experts to vote on the drug for ALS. The drug has been the focal point of a lobbying campaign by patients, their families and lawmakers. FDA reviewers said Monday, March 28, 2022 the single study from Amylyx Pharmaceuticals was “not persuasive” due to missing data, errors in enrolling patients and other problems. (AP Photo/Jacquelyn Martin, File)

Deadline approaches to pass bill affecting employment for 3,500 FDA workers

Thousands of employees at the Food and Drug Administration would face potential furlough if user fee program legislation isn’t passed by Sept. 30.

Read more
Amelia Brust/Federal News Network

VA launches strategic review, considers schedule changes amid concerns with new EHR

Read more
Jon Tester, John Boozman, James Lankford

Lawmakers introduce bill to expand tuition assistance options for military

Read more

Private sector should ‘complement,’ not replace VA health care

Read more